This inventor holds 4 USPTO granted patents. Top assignee: Dainippon Pharmaceutical Company, Limited. Active years: 1991-2002.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1991-2002
Title: Hitoshi Kawashima: Innovator in Pharmaceutical Preparations
Introduction
Hitoshi Kawashima is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid preparations. With a total of 4 patents to his name, Kawashima's work has had a considerable impact on drug formulation and delivery.
Latest Patents
One of his latest patents involves a solid preparation that comprises a crystal of a specific compound known as Compound A. This invention focuses on creating a solid preparation with excellent stability and content uniformity of Compound A. The preparation is designed to have a particle size not larger than 100 µm at the cumulative weight distribution value of 50%, and not larger than 200 µm at the cumulative weight distribution value of 95%. The process includes preparing granules of the crystal with fillers, disintegrants, and binders, followed by mixing these granules with external excipients.
Career Highlights
Kawashima is associated with Dainippon Pharmaceutical Company, Limited, where he has been able to apply his innovative ideas in a practical setting. His work has contributed to advancements in pharmaceutical formulations, enhancing the effectiveness and stability of medications.
Collaborations
Throughout his career, Kawashima has collaborated with notable colleagues such as Junichi Yamagishi and Ryuji Furuta. These collaborations have fostered a creative environment that has led to the development of groundbreaking pharmaceutical solutions.
Conclusion
Hitoshi Kawashima's contributions to the pharmaceutical industry through his innovative patents and collaborations highlight his role as a key inventor in the field. His work continues to influence the development of effective drug formulations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
